BRCA2 mutations were detected in 31 (5.0%) early onset patients, 15 (12.1%) patients with bilateral breast cancer, 2 (33.3%) patient with breast and ovarian cancer, 3 (4.6%) patients with multiple organ cancers, 1 (5.9%) male breast cancer patient, and 12 (15.2%) patients having two or more of these high risks (Table 2). The gene discussed is BRCA2; the disease is ovarian carcinoma.